World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
125
Citations
74845
World Ranking
3035
National Ranking
79

Overview

Hervé Dombret is affiliated with Université Paris Cité in France and has contributed extensively to the field of medicine, with a particular focus on hematology. Their research encompasses subfields including public health, environmental and occupational health, genetics, molecular biology, and oncology.

The scientist's work covers several main topics including:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Histone Deacetylase Inhibitors Research

Frequent coauthors collaborating with Hervé Dombret include:

  • Nicolas Boissel (56 joint publications)
  • Pau Montesinos (43 joint publications)
  • Claude Preudhomme (43 joint publications)
  • Raphaël Itzykson (39 joint publications)
  • Emmanuel Raffoux (37 joint publications)

The scientist has published mainly in the following venues:

  • Blood (73 publications)
  • Clinical Lymphoma Myeloma & Leukemia (17 publications)
  • Leukemia (11 publications)
  • HemaSphere (10 publications)
  • Blood Advances (8 publications)

Representative recent papers authored by Hervé Dombret include:

  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN, 2022, Blood
  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, 2022, Blood
  • Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission, 2020, New England Journal of Medicine
  • Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial, 2023, The Lancet
  • A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia, 2022, Nature Medicine

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

    Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum

  • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

    Max S. Topp;Nicola Gökbuget;Anthony S. Stein;Gerhard Zugmaier

  • Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

    Eric L. Sievers;Richard A. Larson;Edward A. Stadtmauer;Elihu Estey

  • International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

    Hervé Dombret;John F. Seymour;Aleksandra Butrym;Agnieszka Wierzbowska

  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini

  • A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

    Pierre Fenaux;Claude Chastang;Sylvie Chevret;Miguel Sanz

  • Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

    Sylvie Castaigne;Cécile Pautas;Christine Terré;Emmanuel Raffoux

  • A 17-gene stemness score for rapid determination of risk in acute leukaemia

    Stanley W. K. Ng;Amanda Mitchell;James A. Kennedy;James A. Kennedy;James A. Kennedy;Weihsu C. Chen

  • Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials

    Robert Kerrin Hills;Sylvie Castaigne;Frederick R. Appelbaum;Jacques Delaunay

  • Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials

    Nicolas Boissel;Marie-Françoise Auclerc;Véronique Lhéritier;Yves Perel

  • Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

    Nicola Gökbuget;Hervé Dombret;Massimiliano Bonifacio;Albrecht Reichle

  • Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

    Françoise Huguet;Thibaut Leguay;Emmanuel Raffoux;Xavier Thomas

  • OUTCOME OF TREATMENT IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: ANALYSIS OF THE LALA-94 TRIAL

    Xavier Thomas;Jean Michel Boiron;Françoise Huguet;Hervé Dombret

  • Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

    Claude Preudhomme;Christophe Sagot;Nicolas Boissel;Jean-Michel Cayuela

  • Prognostic significance of survivin expression in diffuse large B-cell lymphomas

    Colette Adida;Corinne Haioun;Philippe Gaulard;Eric Lepage

  • An update of current treatments for adult acute myeloid leukemia

    Hervé Dombret;Claude Gardin

  • Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

    Richard A. Larson;Eric L. Sievers;Eric L. Sievers;Edward A. Stadtmauer;Bob Löwenberg

  • All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.

    L Degos;H Dombret;C Chomienne;M T Daniel

Frequent Co-Authors

Emmanuel Raffoux
Emmanuel Raffoux Hôpital Saint-Louis
Nicolas Boissel
Nicolas Boissel Université Paris Cité
Claude Preudhomme
Claude Preudhomme University of Lille
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Norbert Ifrah
Norbert Ifrah Grenoble Alpes University
Sylvie Castaigne
Sylvie Castaigne Versailles Saint-Quentin-en-Yvelines University
Stéphane de Botton
Stéphane de Botton Institut Gustave Roussy
Elizabeth Macintyre
Elizabeth Macintyre Necker-Enfants Malades Hospital
Aline Renneville
Aline Renneville Institut Gustave Roussy
Sylvie Chevret
Sylvie Chevret Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering Medicine in the USA, there are multiple related online degrees that can support diverse career goals in healthcare. Many individuals choose to pursue non-physician roles that are critical to the functioning of medical systems. For instance, if you're interested in healthcare leadership, cahme accredited online healthcare administration programs offer a rigorous way to enter management-level positions without stepping away from your current responsibilities.

For registered nurses eager to further their careers but with limited flexibility for in-person learning, flexible rn to bsn programs allow for completion of degree requirements online, often with no clinicals required. Similarly, those wishing to pursue advanced nursing practice may be interested in the shortest dnp programs online or other dnp online programs that offer accelerated or more approachable pathways to a Doctor of Nursing Practice degree.

Exploring these pathways can help you find a healthcare role that matches your passion and life circumstances—whether that’s on the front lines or in vital support and leadership roles.

Best Scientists Citing Hervé Dombret

Trending Scientists